Creatine monohydrate

Drug Profile

Creatine monohydrate

Alternative Names: AL-02; AL-05; ALS-02; ALS-05; ALS-08/celecoxib; ALS-08/minocycline; CMT-02; CTD-02; CTD-09; DMD-02; HD-02; NEOtine; PD-01; PD-02; PD-04; PD-06; PURE ENERGY

Latest Information Update: 03 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avicena Group
  • Class Amino acids; Guanidines; Neuroprotectants; Small molecules
  • Mechanism of Action Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease; Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Huntington's disease; Metabolic disorders; Neuromuscular disorders; Parkinson's disease

Most Recent Events

  • 03 Jun 2010 No development reported - Phase-I for Neuromuscular disorders in USA (PO)
  • 03 Jun 2010 No development reported - Phase-II for Huntington's disease in USA (PO)
  • 03 Jun 2010 No development reported - Phase-III for Amyotrophic lateral sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top